On March 17, 2025, ITF Therapeutics announced the presentation of seven abstracts at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held March 16-19, 2025, in Dallas, Texas. The poster presentations include data from the Phase 3 EPIDYS study and the company’s ongoing open-label extension study in patients with Duchenne muscular dystrophy (DMD) treated with givinostat.
Analyses assess the long-term safety and efficacy of givinostat as identified through measures including data on disease progression and respiratory function. Please see the Indication and Important Safety Information for DUVYZAT™ (givinostat) below.
To read their full release, please click here.